Abstract:Background: Lenvatinib is an important molecular target drug for the treatment of advanced hepatocellular carcinoma (HCC). However, the application of molecular targeted therapies for HCC also faces some challenges. Cumulative evidence has also shown that curcumol is a potential anti-HCC drug. Curcumol can be used as a chemosensitizer to enhance the antitumor effect of chemotherapeutic drugs. The purpose of our study is to explore the effect of curcumol combined with lenvatinib on HCC. Methods: The antitumor effects of curcumol or/and lenvatinib on Huh 7 cells of the HCC cell line were examined using the cell counting kit-8 (CCK-8) assay, colony formation assay, and transwell assay. For in vivo investigation, the effect on subcutaneous growth was also determined in nude mice. Changes in autophagy were determined by transmission electron microscope (TEM). Protein levels of apoptotic-related factors, epithelial mesenchymal transition (EMT)-related factors, autophagy factors, and N-cadherin and janus tyrosine kinase 2 (JAK2)/signal transducers and activators of transcription 3 (STAT3) were examined by Western blot. Results: In this study, we found that curcumol or lenvatinib could promote HCC cell apoptosis in vitro and inhibit the growth of HCC tumors in vivo (curcumol or lenvatinib group compared with control group, p < 0.05). While combination with curcumol treatment could improve the effect of lenvatinib on promoting cell apoptosis of HCC in vitro and inhibiting the growth of HCC tumors in vivo (combination group compared with lenvatinib group, p < 0.05). Curcumol combined with lenvatinib could induce more autolysosome formation detected by TEM. Mechanically, curcumol or lenvatinib could increase the expression of Bcl-2-associated X protein (Bax), E-cadherin, UNC-51-like kinase 1 (ULK), and microtubule-associated protein 1 light chain 3 (LC3B) II/I, whereas it reduced the expression of B-cell lymphoma-2 (Bcl-2), JAK2/STAT3 (curcumol or lenvatinib group compared with control group, p < 0.05). Furthermore, combined with curcumol treatment could increase the expression of Bax, E-cadherin, ULK, and LC3B II/I, whereas it reduced the expression of Bcl-2, N-cadherin, and JAK2/STAT3 (combination group compared with lenvatinib group, p < 0.05). These findings suggest that curcumol enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells. Conclusion: Curcumol enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells.

Trichostatin A Improves the Anticancer Activity of Low Concentrations of Curcumin in Human Leukemia Cells.

Water-soluble Antioxidants Improve the Antioxidant and Anticancer Activity of Low Concentrations of Curcumin in Human Leukemia Cells.

Quercetin and Trichostatin A Cooperatively Kill Human Leukemia Cells

Synergistic killing of human leukemia cells by antioxidants and trichostatin A

The enhanced inhibitory effects of curcumin combined with adriamycin on the growth of human leukemia cell line HL-60/ADR with multidrug resistance

Novel Curcumin Liposome Modified with Hyaluronan Targeting CD44 Plays an Anti-Leukemic Role in Acute Myeloid Leukemia in Vitro and in Vivo.

Curcumin Enhances the Antitumor Effect of Abt-737 Via Activation of the Ros-Ask1-Jnk Pathway in Hepatocellular Carcinoma Cells

[Inhibition of Curcumin on Histone Deacetylase and Expression Promotion of P21 (WAF1/CIP1) in HepG2 Cells].

Regulation of Histone Acetylation and Apoptosis by Trichostatin in HL-60 Cells.

Curcumin augments therapeutic efficacy of TRAIL-based immunotoxins in leukemia

Trichostatin C Synergistically Interacts with DNMT Inhibitor to Induce Antineoplastic Effect via Inhibition of Axl in Bladder and Lung Cancer Cells

[Effect of Trichostatin A on Histone Acetylation Level and Apoptosis in HL-60 Cells].

Curcumin Induces Apoptosis Via Simultaneously Targeting Akt/Mtor and Raf/Mek/Erk Survival Signaling Pathways in Human Leukemia Thp-1 Cells

Curcumol Enhances the Antitumor Effect of Lenvatinib on Hepatocellular Carcinoma Cells

Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota

Antitumor Activity of Curcumin by Modulation of Apoptosis and Autophagy in Human Lung Cancer A549 Cells Through Inhibiting PI3K/Akt/mTOR Pathway.

Low-dose Curcumin Leads to the Inhibition of Tumor Growth Via Enhancing CTL-mediated Antitumor Immunity

Curcumin, a Potent Anti-Tumor Reagent, is a Novel Histone Deacetylase Inhibitor Regulating B-NHL Cell Line Raji Proliferation

Effect of Curcumin in Combination with STI571 on K562 Cells and Histone Deacetylase 8

Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop

Evaluation of curcumin, a natural product in turmeric, on Burkitt lymphoma and acute myeloid leukemia cancer stem cell markers